Tirzepatide · 10 mg Vial
Tirzepatide Dosage calculations for
- Research frequency
- Once weekly by subcutaneous administration in the cited human trials.
- Weekly research range
- The cited programs evaluated target amounts through 15 mg weekly after stepwise escalation.
- Vial size
- The 10 mg label is total nominal vial content, not a weekly amount.
- Vial coverage
- At the 2.5 mg starting stage, one vial supplies 4 full weekly amounts. At the 15 mg research stage, the 15 mg amount requires 2 separate 10 mg vials by nominal mass. These are mass calculations, not vial storage or discard periods.
Standard Weekly Escalation Schedule
| Study Phase | Weekly Amount | Volume |
|---|---|---|
| Weeks 1 to 4 | 2.5 mg | 0.5 mL |
| Weeks 5 to 8 | 5 mg | 1 mL |
| Weeks 9 to 12 | 7.5 mg | 1.5 mL |
| Weeks 13 to 16 | 10 mg | 2 mL |
| Weeks 17 to 20 | 12.5 mg | 2.5 mL |
| Weeks 21+ | 15 mg | 3 mL |
3 ml conversion
5 mg + 3 ml = 1.67 mg/ml. Choose your vial strength to update the units below.
| Source dose | U-100 syringe |
|---|---|
| 2.5 mg | 150 units |
| 5 mg | 300 units |
| 7.5 mg | 450 units |
| 10 mg | 600 units |
| 12.5 mg | 750 units |
| 15 mg | 900 units |